{
    "root": "308f933c-10fe-a0a3-e063-6294a90a2246",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rosuvastatin Calcium",
    "value": "20250317",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (35 .MU.M)",
            "code": "40UAA97IT9"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "MEGLUMINE",
            "code": "6HG8UB2MUY",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09415"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "ROSUVASTATIN CALCIUM",
            "code": "83MVU38M7Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77249"
        }
    ],
    "indications": {
        "text": "rosuvastatin tablets indicated : \u2022 reduce risk major cardiovascular ( cv ) events ( cv death , nonfatal myocardial infarction , nonfatal stroke , arterial revascularization procedure ) adults without established coronary heart disease increased risk cv disease based age , high-sensitivity c-reactive protein ( hscrp ) \u22652 mg/l , least one additional cv risk factor . \u2022 adjunct diet : reduce low-density lipoprotein cholesterol ( ldl-c ) adults primary hyperlipidemia . reduce ldl-c slow progression atherosclerosis adults . reduce ldl-c adults pediatric patients aged 8 years older heterozygous familial hypercholesterolemia ( hefh ) . \u2022 adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 7 years older homozygous familial hypercholesterolemia ( hofh ) . \u2022 adjunct diet treatment adults : primary dysbetalipoproteinemia . hypertriglyceridemia .",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "atherosclerosis (DOID:1936)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1936"
            },
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "take orally without food , time day . ( 2.1 ) assess ldl-c clinically appropriate , early 4 weeks initiating rosuvastatin calcium , adjust necessary . ( 2.1 ) adults : recommended range 5 40 mg daily . ( 2.1 ) pediatric patients hefh : recommended range 5 10 mg daily patients aged 8 less 10 years age , 5 20 mg daily patients aged 10 years older . ( 2.2 ) pediatric patients hofh : recommended 20 mg daily patients aged 7 years older . ( 2.2 ) asian patients : initiate 5 mg daily . consider risks benefits treatment adequately controlled doses 20 mg daily . ( 2.4 ) patients severe renal impairment ( hemodialysis ) : initiate 5 mg daily ; exceed 10 mg daily . ( 2.5 ) full prescribing information rosuvastatin calcium modifications due . ( 2.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "rosuvastatin tablets , usp supplied : 10 mg , pink , round shaped , biconvex , film coated tablets debossed `` r10 `` one side plain side . ndc : 70518-2542-00 ndc : 70518-2542-01 ndc : 70518-2542-02 ndc : 70518-2542-03 packaging ; 30 1 blister pack packaging : 90 1 bottle plastic packaging : 100 1 box packaging : 1 1 pouch storage store controlled room temperature , 20\u00bac 25\u00bac ( 68\u00baf 77\u00baf ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "rosuvastatin calcium contraindicated following conditions acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . hypersensitivity rosuvastatin excipients rosuvastatin calcium . hypersensitivity including rash , pruritus , urticaria , angioedema reported rosuvastatin calcium [ ( 6.1 ) ] .",
    "indications_original": "Rosuvastatin tablets are indicated:\n                  \n                     \u2022 To reduce the risk of major\u00a0adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) \u22652 mg/L, and at least one additional\u00a0CV risk factor.\n                  \n                  \u2022\u00a0As an adjunct to diet to:\u00a0\n                  \n                  \u00a0\u00a0\u00a0\u00a0o Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.\u00a0 \n    \u00a0\u00a0\u00a0\u00a0o Reduce LDL-C and slow the progression of atherosclerosis in adults.\u00a0 \n    \u00a0\u00a0\u00a0\u00a0o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).\n \n                  \u2022\u00a0As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).\u00a0\n                  \u2022\u00a0As an adjunct to diet for the treatment of adults with:\u00a0 \n    \u00a0\u00a0\u00a0\u00a0o Primary dysbetalipoproteinemia.\u00a0\n \n                  \u00a0\u00a0\u00a0\u00a0o Hypertriglyceridemia.",
    "contraindications_original": "Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin calcium, and adjust dosage if necessary. ( 2.1 ) Adults: Recommended dosage range is 5 to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH: Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.2 ) Pediatric Patients with HoFH: Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 ) See full prescribing information for rosuvastatin calcium dosage and administration modifications due to drug interactions. ( 2.6 )",
    "warningsAndPrecautions_original": "Rosuvastatin tablets, USP are supplied as:\n                  10 mg, Pink, round shaped, biconvex, film coated tablets debossed with \"R10\" on one side and plain on other side.\n                  \n                  NDC: 70518-2542-00\n                  NDC: 70518-2542-01\n                  NDC: 70518-2542-02\n                  NDC: 70518-2542-03\n                  PACKAGING; 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Storage\n                  Store at controlled room temperature, 20\u00baC to 25\u00baC (68\u00baF to 77\u00baF); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Rosuvastatin calcium is contraindicated in the following conditions\n                  \n                     Acute liver failure or decompensated cirrhosis\n  \n   [\n   \n    see Warnings and Precautions (5.3)].\n  \n   \n                     \n                  \n                  \n                     \n                        \u00a0Hypersensitivity to rosuvastatin or any excipients in rosuvastatin calcium. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin calcium\n  \n   \n                           \n                              [\n     \n      see Adverse Reactions (6.1)].",
    "drug": [
        {
            "name": "Rosuvastatin Calcium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77249"
        }
    ]
}